

REGENERON PHARMACEUTICALS INC

Form 8-K

May 05, 2003

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **May 5, 2003**

**REGENERON PHARMACEUTICALS, INC.**

---

(Exact name of registrant as specified in its charter)

NEW YORK

0-19034

No. 13-3444607

---

(State or other jurisdiction  
of incorporation)

---

(Commission  
File Number)

---

(IRS Employer  
Identification No.)

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

10591-6707

---

(Address of principal executive offices)

---

(Zip Code)

Registrant's telephone number, (914)  
including area code 347-7000

---

NOT APPLICABLE

(Former name or former address, if changed since last report)

**TABLE OF CONTENTS**

INFORMATION TO BE INCLUDED IN REPORT

Item 7. Financial Statements and Exhibits.

Item 12. Results of Operations and Financial Condition.

SIGNATURE

PRESS RELEASE

---

**Table of Contents**

**INFORMATION TO BE INCLUDED IN REPORT**

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits

99(a) Press Release dated May 5, 2003.

**Item 12. Results of Operations and Financial Condition.**

On May 5, 2003, we reported our first quarter 2003 results. Our first quarter 2003 results are discussed in detail in the press release attached hereto as Exhibit 99(a), which is incorporated by reference in its entirety. The information furnished under Item 12 of this Current Report on Form 8-K, including Exhibit 99(a), shall be deemed filed for purposes of the Securities Exchange Act of 1934, as amended and incorporated by reference in any of our filings under the Securities Act of 1933, as amended, as may be specified in such filing.

-2-

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Regeneron Pharmaceuticals, Inc.**

By: /s/ Stuart Kolinski

Stuart Kolinski  
Vice President & General Counsel

Date: May 5, 2003